A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2015 - September 30, 2022